SHARE
Prostate Cancer Market

Prostate Cancer - Global Market Outlook (2017-2026)

4.5 (29 reviews)
Published: August 2019 ID: SMRC18457
4.5 (29 reviews)
Published: August 2019 ID: SMRC18457

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Prostate Cancer market is growing at a CAGR of 10.3% during the forecast period. Some of the key factors such as improved diagnosis and frequency rates in industrial economies, rapidly growing geriatric population, and the high demand for effective treatments are propelling the market growth. However, high price for treatment, lack of awareness and short accessibility of health care services in the small regions which are hampering the growth of the market. 

Prostate cancer is one of the most ordinary types of cancer in men which is caused by the irregular growth of tissues in the prostate gland that produce seminal fluid. Various types of prostate cancer grow up slowly and may require minimal or no treatment, other types are hostile and can increase quickly. This needs novel drugs that will address the unmet desires low cost and enhanced survival time.

Based on Therapy, Biologic therapy is a treatment for patients with prostate cancer that involves utilize of existing organisms, substances plagiaristic from living organisms, or laboratory formed versions of living organisms. Biological therapies use diverse ways to rouse the immune system and stop tumor cells from rising. For patients with cancer, biological therapies may be used to treat the cancer itself or the side effects of other cancer treatments.

By Geography, Asia Pacific is expected to exhibit the utmost growth on account of the existence of untapped opportunity in the rising economies such as India and China. As well, rising healthcare expenditure has caused an increase in the implementation of technically advanced commodities, which is likely to boost county market growth.

Some of the key players profiled in the Prostate Cancer Market include Astellas, Inc., AstraZeneca plc, Bristol Myers Squibb (BMS), Johnson & Johnson, NOVARTIS, Sanofi S.A, TOLMAR Inc., Tokai Pharmaceuticals, Progenics Pharmaceuticals Inc., OncoGenex Pharmaceuticals Inc., OncBioMune Pharmaceuticals Inc., Endo Pharmaceuticals, and Bayer Pharma AG.
    
Types Covered:
• Hormone Sensitive
• Hormone Refractory

Therapies Covered:
• Focal Therapies
• Biologic Therapy
• Cryosurgery
• Immunotherapy
• Therapeutic Vaccines
• Radiation Therapy
• Chemotherapy
• Surgery
• Targeted Therapy
• Bone Metastasis
• Hormonal Therapy 

Diagnostic Techniques Covered:
• Prostate Specific Antigen Test (PSA)
• Digital Rectal Exam (DRE) 

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals
• Pharmacies
• Specialty Clinics
• Other End Users    

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players 
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary                        
                          
2 Preface       
                 
 2.1 Abstract                        
 2.2 Stake Holders                       
 2.3 Research Scope                       
 2.4 Research Methodology                      
  2.4.1 Data Mining                      
  2.4.2 Data Analysis                      
  2.4.3 Data Validation                      
  2.4.4 Research Approach                      
 2.5 Research Sources                       
  2.5.1 Primary Research Sources                     
  2.5.2 Secondary Research Sources                     
  2.5.3 Assumptions                      
                          
3 Market Trend Analysis                       
 3.1 Introduction                       
 3.2 Drivers                        
 3.3 Restraints                       
 3.4 Opportunities                       
 3.5 Threats                        
 3.6 End User Analysis                       
 3.7 Emerging Markets                       
 3.8 Futuristic Market Scenario                      
                          
4 Porters Five Force Analysis                       
 4.1 Bargaining power of suppliers                      
 4.2 Bargaining power of buyers                      
 4.3 Threat of substitutes                      
 4.4 Threat of new entrants                      
 4.5 Competitive rivalry                       
                          
5 Global Prostate Cancer Market, By Type                      
 5.1 Introduction                       
 5.2 Hormone Sensitive                       
 5.3 Hormone Refractory                      
                          
6 Global Prostate Cancer Market, By Therapy                     
 6.1 Introduction                       
 6.2 Focal Therapies                       
 6.3 Biologic Therapy                       
 6.4 Cryosurgery                       
 6.5 Immunotherapy                       
  6.5.1 Vaccines                       
 6.6 Therapeutic Vaccines                      
  6.6.1 Provenge (Sipuleucel-T)                     
 6.7 Radiation Therapy                       
  6.7.1 External Beam                      
   6.7.1.1 Stereotactic Body                     
   6.7.1.2 Proton Beam                     
   6.7.1.3 Intensity Modulated                    
   6.7.1.4 3D Conformal                     
  6.7.2 Brachytherapy                      
   6.7.2.1 Temporary                     
   6.7.2.2 Permanent                     
 6.8 Chemotherapy                       
  6.8.1 Vinorelbine                      
  6.8.2 Vinblastine                      
  6.8.3 Taxotere (Docetaxel)                     
  6.8.4 Taxanes                       
  6.8.5 Jevtana (Cabazitaxel)                     
  6.8.6 Etoposide                      
  6.8.7 Cytotoxic Drugs                      
  6.8.8 Carboplatin                      
  6.8.9 Antimetabolites                      
  6.8.10 Anthracyclines                      
  6.8.11 Alkylating Agents                      
 6.9 Surgery                        
  6.9.1 Trans Urethral Resection (TUR)                    
  6.9.2 Radical Prostatectomy                     
  6.9.3 Orchidectomy                      
 6.10 Targeted Therapy                       
  6.10.1 Tyrosine Kinase Inhibitors                     
  6.10.2 Signal Transduction Inhibitor                     
  6.10.3 Monoclonal Antibodies                     
  6.10.4 Apoptosis Inducing Drugs                     
  6.10.5 Angiogenesis Inhibitor                     
 6.11 Bone Metastasis                       
  6.11.1 Zometa (Zoledronic Acid)                     
  6.11.2 Xofigo (Radium 223 Dichloride)                    
  6.11.3 Xgeva (Denosumab)                     
  6.11.4 Alpharadin                      
 6.12 Hormonal Therapy                       
  6.12.1 Aromatase Inhibitors                     
  6.12.2 Estrogen-Receptor Modulators (Serms)                    
  6.12.3 Luteinizing Hormone–Releasing Hormone (LHRH) Analogs                  
   6.12.3.1 Lupron                      
   6.12.3.2 Zoladex                      
   6.12.3.3 Decapeptyl                     
   6.12.3.4 Eligard                      
   6.12.3.5 Vantas                      
   6.12.3.6 Leuplin                      
   6.12.3.7 Trelstar (Triptorelin Pamoate)                    
   6.12.3.8 Firmagon (Degarelix)                    
   6.12.3.9 Casodex (Bicalutamide)                    
  6.12.4 Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists                  
   6.12.4.1 Zytiga                      
   6.12.4.2 Gonax                      
   6.12.4.3 Xtandi (Enzalutamide)                    
  6.12.5 Anti–Androgens                        
   6.12.5.1 Casodex                      
   6.12.5.2 Xtandi or MDV3100                    
   6.12.5.3 Xtandi US or MDV3100                    
  6.12.6 Other Hormonal Therapies                     
                          
7 Global Prostate Cancer Market, By Diagnostic Technique                    
 7.1 Introduction                       
 7.2 Prostate Specific Antigen Test (PSA)                     
 7.3 Digital Rectal Exam (DRE)                      
                          
8 Global Prostate Cancer Market, By End User                     
 8.1 Introduction                       
 8.2 Ambulatory Surgical Centers                      
 8.3 Hospitals                        
 8.4 Pharmacies                       
 8.5 Specialty Clinics                       
 8.6 Other End Users                       
                          
9 Global Prostate Cancer Market, By Geography                     
 9.1 Introduction                       
 9.2 North America                       
  9.2.1 US                       
  9.2.2 Canada                       
  9.2.3 Mexico                       
 9.3 Europe                        
  9.3.1 Germany                       
  9.3.2 UK                       
  9.3.3 Italy                       
  9.3.4 France                       
  9.3.5 Spain                       
  9.3.6 Rest of Europe                      
 9.4 Asia Pacific                       
  9.4.1 Japan                       
  9.4.2 China                       
  9.4.3 India                       
  9.4.4 Australia                       
  9.4.5 New Zealand                      
  9.4.6 South Korea                      
  9.4.7 Rest of Asia Pacific                      
 9.5 South America                       
  9.5.1 Argentina                      
  9.5.2 Brazil                       
  9.5.3 Chile                       
  9.5.4 Rest of South America                     
 9.6 Middle East & Africa                      
  9.6.1 Saudi Arabia                      
  9.6.2 UAE                       
  9.6.3 Qatar                       
  9.6.4 South Africa                      
  9.6.5 Rest of Middle East & Africa                     
                          
10 Key Developments                        
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures                   
 10.2 Acquisitions & Mergers                      
 10.3 New Product Launch                      
 10.4 Expansions                       
 10.5 Other Key Strategies                      
                          
11 Company Profiling   
                    
 11.1 Astellas, Inc.                       
 11.2 AstraZeneca plc                       
 11.3 Bristol Myers Squibb (BMS)                      
 11.4 Johnson & Johnson                       
 11.5 NOVARTIS                       
 11.6 Sanofi S.A                       
 11.7 TOLMAR Inc.                       
 11.8 Tokai Pharmaceuticals                      
 11.9 Progenics Pharmaceuticals Inc.                     
 11.10 OncoGenex Pharmaceuticals Inc.                     
 11.11 OncBioMune Pharmaceuticals Inc.                     
 11.12 Endo Pharmaceuticals                      
 11.13 Bayer Pharma AG 


List of Tables                         
1 Global Prostate Cancer Market Outlook, By Region (2016-2026) (US $MN)                   
2 Global Prostate Cancer Market Outlook, By Type (2016-2026) (US $MN)                   
3 Global Prostate Cancer Market Outlook, By Hormone Sensitive (2016-2026) (US $MN)                 
4 Global Prostate Cancer Market Outlook, By Hormone Refractory (2016-2026) (US $MN)                 
5 Global Prostate Cancer Market Outlook, By Therapy (2016-2026) (US $MN)                  
6 Global Prostate Cancer Market Outlook, By Focal Therapies (2016-2026) (US $MN)                  
7 Global Prostate Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)                  
8 Global Prostate Cancer Market Outlook, By Cryosurgery (2016-2026) (US $MN)                  
9 Global Prostate Cancer Market Outlook, By Immunotherapy (2016-2026) (US $MN)                  
10 Global Prostate Cancer Market Outlook, By Vaccines (2016-2026) (US $MN)                  
11 Global Prostate Cancer Market Outlook, By Therapeutic Vaccines (2016-2026) (US $MN)                 
12 Global Prostate Cancer Market Outlook, By Provenge (Sipuleucel-T) (2016-2026) (US $MN)                 
13 Global Prostate Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)                 
14 Global Prostate Cancer Market Outlook, By External Beam (2016-2026) (US $MN)                  
15 Global Prostate Cancer Market Outlook, By Brachytherapy (2016-2026) (US $MN)                  
16 Global Prostate Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)                  
17 Global Prostate Cancer Market Outlook, By Vinorelbine (2016-2026) (US $MN)                  
18 Global Prostate Cancer Market Outlook, By Vinblastine (2016-2026) (US $MN)                  
19 Global Prostate Cancer Market Outlook, By Taxotere (Docetaxel) (2016-2026) (US $MN)                 
20 Global Prostate Cancer Market Outlook, By Taxanes (2016-2026) (US $MN)                  
21 Global Prostate Cancer Market Outlook, By Jevtana (Cabazitaxel) (2016-2026) (US $MN)                 
22 Global Prostate Cancer Market Outlook, By Etoposide (2016-2026) (US $MN)                  
23 Global Prostate Cancer Market Outlook, By Cytotoxic Drugs (2016-2026) (US $MN)                  
24 Global Prostate Cancer Market Outlook, By Carboplatin (2016-2026) (US $MN)                  
25 Global Prostate Cancer Market Outlook, By Antimetabolites (2016-2026) (US $MN)                  
26 Global Prostate Cancer Market Outlook, By Anthracyclines (2016-2026) (US $MN)                  
27 Global Prostate Cancer Market Outlook, By Alkylating Agents (2016-2026) (US $MN)                 
28 Global Prostate Cancer Market Outlook, By Surgery (2016-2026) (US $MN)                  
29 Global Prostate Cancer Market Outlook, By Trans Urethral Resection (TUR) (2016-2026) (US $MN)                
30 Global Prostate Cancer Market Outlook, By Radical Prostatectomy (2016-2026) (US $MN)                 
31 Global Prostate Cancer Market Outlook, By Orchidectomy (2016-2026) (US $MN)                  
32 Global Prostate Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)                 
33 Global Prostate Cancer Market Outlook, By Tyrosine Kinase Inhibitors (2016-2026) (US $MN)                 
34 Global Prostate Cancer Market Outlook, By Signal Transduction Inhibitor (2016-2026) (US $MN)                
35 Global Prostate Cancer Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)                 
36 Global Prostate Cancer Market Outlook, By Apoptosis Inducing Drugs (2016-2026) (US $MN)                 
37 Global Prostate Cancer Market Outlook, By Angiogenesis Inhibitor (2016-2026) (US $MN)                 
38 Global Prostate Cancer Market Outlook, By Bone Metastasis (2016-2026) (US $MN)                  
39 Global Prostate Cancer Market Outlook, By Zometa (Zoledronic Acid) (2016-2026) (US $MN)                 
40 Global Prostate Cancer Market Outlook, By Xofigo (Radium 223 Dichloride) (2016-2026) (US $MN)                
41 Global Prostate Cancer Market Outlook, By Xgeva (Denosumab) (2016-2026) (US $MN)                 
42 Global Prostate Cancer Market Outlook, By Alpharadin (2016-2026) (US $MN)                  
43 Global Prostate Cancer Market Outlook, By Hormonal Therapy (2016-2026) (US $MN)                 
44 Global Prostate Cancer Market Outlook, By Aromatase Inhibitors (2016-2026) (US $MN)                 
45 Global Prostate Cancer Market Outlook, By Estrogen-Receptor Modulators (Serms) (2016-2026) (US $MN)               
46 Global Prostate Cancer Market Outlook, By Luteinizing Hormone–Releasing Hormone (LHRH) Analogs (2016-2026) (US $MN)              
47 Global Prostate Cancer Market Outlook, By Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists (2016-2026) (US $MN)             
48 Global Prostate Cancer Market Outlook, By Anti–Androgens (2016-2026) (US $MN)                  
49 Global Prostate Cancer Market Outlook, By Other Hormonal Therapies (2016-2026) (US $MN)                 
50 Global Prostate Cancer Market Outlook, By Diagnostic Technique (2016-2026) (US $MN)                 
51 Global Prostate Cancer Market Outlook, By Prostate Specific Antigen Test (PSA) (2016-2026) (US $MN)                
52 Global Prostate Cancer Market Outlook, By Digital Rectal Exam (DRE) (2016-2026) (US $MN)                 
53 Global Prostate Cancer Market Outlook, By End User (2016-2026) (US $MN)                  
54 Global Prostate Cancer Market Outlook, By Ambulatory Surgical Centers (2016-2026) (US $MN)                
55 Global Prostate Cancer Market Outlook, By Hospitals (2016-2026) (US $MN)                  
56 Global Prostate Cancer Market Outlook, By Pharmacies (2016-2026) (US $MN)                  
57 Global Prostate Cancer Market Outlook, By Specialty Clinics (2016-2026) (US $MN)                  
58 Global Prostate Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)                  
                          
NOTE: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in the same manner above.          

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials